明德生物2月2日获融资买入925.88万元，融资余额1.29亿元

Group 1 - The core point of the news is that Mingde Biological experienced a slight decline in stock price, with a trading volume of 59.55 million yuan on February 2, and notable financing activities indicating a high level of market interest [1] - On February 2, Mingde Biological had a financing buy-in amount of 9.26 million yuan and a net financing buy of 0.53 million yuan, with a total financing and securities balance of 130 million yuan, which is 2.91% of its circulating market value [1] - The company’s main business includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, with a revenue composition of 65.04% from in vitro diagnostic products, 21.91% from third-party medical testing, and 13.05% from agency business and others [1] Group 2 - As of January 20, the number of shareholders of Mingde Biological decreased by 15.73% to 24,800, while the average circulating shares per person increased by 18.66% to 6,302 shares [2] - For the period from January to September 2025, Mingde Biological achieved an operating income of 227 million yuan, a year-on-year increase of 0.53%, but the net profit attributable to the parent company decreased by 83.30% to 13.52 million yuan [2] - The company has distributed a total of 1.76 billion yuan in dividends since its A-share listing, with 875 million yuan distributed in the last three years [2]